Therapeutic activation of LTR/ERV repeat transcription by, for example, low dose DNMT inhibition with azacytidine (DNMTi) can break immune tolerance of cancer cells and revealed a novel quality for ‘epigenetic therapy’ [11, 47]. The gene discussed is DNMT1; the disease is cancer.